Statement of Deficiencies	**(X1) Provider/Supplier/CLIA Identification Number**	**(X3) Date Survey Completed**
	39D0195442	11/05/2025
Name of Provider or Supplier	**Street Address, City, State**	
Brookside Clinical Lab Inc	2901 W Duttons Mill Road, Suite 100, Aston, PA	

For information on the provider's plan to correct this deficiency, please contact the provider or the state survey agency.

(X4) ID Prefix Tag	Summary Statement of Deficiencies
D2016	SUCCESSFUL PARTICIPATION CFR(s): 493.803(a)(b)(c) (a) Each laboratory performing nonwaived testing must successfully participate in a proficiency testing program approved by CMS, if applicable, as described in subpart I of this part for each specialty, subspecialty, and analyte or test in which the laboratory is certified under CLIA. (b) Except as specified in paragraph (c) of this section, if a laboratory fails to participate successfully in proficiency testing for a given specialty, subspecialty, analyte or test, as defined in this section, or fails to take remedial action when an individual fails gynecologic cytology, CMS imposes sanctions, as specified in subpart R of this part. (c) If a laboratory fails to perform successfully in a CMS-approved proficiency testing program, for the initial unsuccessful performance, CMS may direct the laboratory to undertake training of its personnel or to obtain technical assistance, or both, rather than imposing alternative or principle sanctions except when one or more of the following conditions exists: (1) There is immediate jeopardy to patient health and safety. (2) The laboratory fails to provide CMS or a CMS agent with satisfactory evidence that it has taken steps to correct the problem identified by the unsuccessful proficiency testing performance. (3) The laboratory has a poor compliance history. This CONDITION is not met as evidenced by: Based on review of the CASPER 0155 report and graded results from the proficiency testing (PT) organization, College of American Pathologists (CAP), the laboratory failed to successfully participate in PT for Rheumatoid Factor, Qualitative (RF). The laboratory had unsatisfactory scores for the 1st and 2nd Event of 2025. Refer to D2084.
D2084	GENERAL IMMUNOLOGY CFR(s): 493.837(f)

	(f) Failure to achieve satisfactory performance for the same analyte or test in two consecutive testing events or two out of three consecutive testing events is unsuccessful performance. This STANDARD is not met as evidenced by: Based on review of the CASPER 0155D Report and graded results from the proficiency testing (PT) organization, College of American Pathologists (CAP), the laboratory failed to achieve an overall testing score of satisfactory performance for the general immunology analyte: Rheumatoid Factor, Qualitative (RF) . The laboratory had unsatisfactory scores for the 1st and 2nd event of 2025. Findings include: 1. Review of the CASPER 0155D report revealed the following unsatisfactory scores: - 2025 Event 1 RF: 0% - 2025 Event 2 RF: 0% 2. Further review of the laboratory's 2025 CAP PT agency's graded results confirmed the above findings resulting in unsatisfactory performance for the general immunology analyte: RF.